Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Final decision from the European Commission is anticipated within the coming months
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
First and only PARP inhibitor to improve overall survival in early breast cancer
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results
Subscribe To Our Newsletter & Stay Updated
